IPO

Achyut Healthcare Limited IPO

BSE SME

Listed On: Mar 30, 2022 at ₹ 20.10

₹ 240000 /12000 Shares
*Min Investment

Check Allotment

17 Mar, 2022

Open Date

22 Mar, 2022

Close Date

28 Mar, 2022

Allotment Date

30 Mar, 2022

Listing Date
IPO Issue Details
  • Issue Price ₹20 per equity share
  • Face Value ₹10 Per Equity Share
  • Issue Price 1,800,000 Eq Shares of ₹10(aggregating up to ₹3.60 Cr)
  • Listing at BSE SME
  • List Price 20.10
  • Listing Date 2022-03-30
  • Lead Manager GYR Capital Advisors Limited
  • Registrar KFintech Private Limited
IPO Details
  • Retail Portion N/A
IPO Documents
IPO Details


Achyut Healthcare Limited IPO is an SME IPO, priced at ₹20 per equity share. The equity shares have a face value of ₹10 Per Equity Share each and will be listed on the BSE SME platform.

The IPO bidding window is open from Mar 17, 2022 to Mar 22, 2022. The allotment is expected to be finalized on Mar 28, 2022, and the tentative listing date is Mar 30, 2022.


The registrar of the IPO is KFintech Private Limited, and

Read More
IPO Subscription Analysis And Details
Retail
6.75x
Total
4.35x
As onQIB / NIIRetailTotal
Shares Offered / Reserved852,000852,0001,704,000
Day 1 17-03-22 06:00 PM
0.36 x0.63 x0.49 x
Day 2 21-03-22 06:00 PM
1.34 x2.39 x1.86 x
Day 3 22-03-22 06:00 PM
1.95 x6.75 x4.35 x
Valuations
Earnings Per Share (EPS) ₹N/A/-
P/E Ratio N/A
RoNW N/A%
Net Asset Value (NAV) - Post Issue ₹N/A/-
Company Financials
In Crs.
In Cr.
30-Jun-2131-Mar-2131-Mar-2031-Mar-19
About Company

Incorporated in 1996, Achyut Healthcare Limited is engaged in the trading of Pharmaceutical Products. The company has business operations in both domestic and international markets in the countries namely UAE, Kenya, and Nigeria. The company is located in Ahmedabad, Gujarat.The company involves in the trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Cross Carmalose Sod IP/USP, DI Basic Calcium Phosphate IP, DI Ethyl Phthlate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.

Read More
- Promoter(s)

Mahendra Chatrabhuj Raycha

Akshit Mahendra Raycha

Pre Issue Share Holding : 90.28%

Post Issue Share Holding : 66.18%

IPO - Issue Objectives
1